Clovis Oncology (CLVS) Tops Q3 EPS by 25c
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Clovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($1.70), $0.25 better than the analyst estimate of ($1.95).
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades Himax Technologies (HIMX) to Neutral
- ADTRAN, Inc. (ADTN) Tops Q4 EPS by 10c
- Target (TGT) November/December Comps Fell 1.3%; Lowers Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!